EvoEndo

EvoEndo is pioneering a shift in gastrointestinal diagnostics with its FDA-cleared, single-use, ultra-slim endoscopy system designed for sedation-free procedures. The platform combines a disposable scope with a portable controller and utilizes virtual reality for patient distraction, aiming to reduce anesthesia-related risks, lower costs, and improve patient access and convenience. The company's technology is gaining validation through clinical use, with over 2,200 cases completed, and aligns with evolving clinical guidelines, such as the 2025 ACG recommendations for Eosinophilic Esophagitis (EoE), particularly benefiting pediatric populations. EvoEndo operates as a private, commercial-stage company targeting the substantial endoscopy market with a disruptive device-based solution.

Integrated single-use endoscopy system featuring ultra-slim, disposable gastroscopes with four-way steering, a portable controller for high-quality imaging, and a virtual reality-based patient distraction system, designed specifically for sedation-free transnasal and transoral procedures.

EvoEndo competes in the endoscopy market dominated by giants like Olympus, Fujifilm, and Pentax, which focus on reusable scope systems. Its primary differentiation is being the first FDA-cleared system designed specifically for sedation-free use. It also competes with other companies developing single-use endoscopes, but positions itself uniquely by combining ultra-slim design for transnasal access, portability, and integrated patient distraction technology.